WO2005087210A3 - Prevention of retinopathy by inhibition of the visual cycle - Google Patents

Prevention of retinopathy by inhibition of the visual cycle Download PDF

Info

Publication number
WO2005087210A3
WO2005087210A3 PCT/DK2005/000176 DK2005000176W WO2005087210A3 WO 2005087210 A3 WO2005087210 A3 WO 2005087210A3 DK 2005000176 W DK2005000176 W DK 2005000176W WO 2005087210 A3 WO2005087210 A3 WO 2005087210A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
retinopathy
retinal
visual cycle
treatment
Prior art date
Application number
PCT/DK2005/000176
Other languages
French (fr)
Other versions
WO2005087210A2 (en
Inventor
Lars Michael Larsen
Original Assignee
Lars Michael Larsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lars Michael Larsen filed Critical Lars Michael Larsen
Priority to AU2005221283A priority Critical patent/AU2005221283C1/en
Priority to US10/593,261 priority patent/US9421175B2/en
Priority to NZ550340A priority patent/NZ550340A/en
Priority to JP2007503197A priority patent/JP2007529434A/en
Priority to CA2601278A priority patent/CA2601278C/en
Priority to EP05715097.1A priority patent/EP1727529B1/en
Publication of WO2005087210A2 publication Critical patent/WO2005087210A2/en
Publication of WO2005087210A3 publication Critical patent/WO2005087210A3/en
Priority to IL178116A priority patent/IL178116A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to compounds capable of inhibiting the visual cycle and/or dark adaptation and their use for treatment and prevention of non-degenerative retinal diseases with specific emphasis on the prevention and treatment of diabetic retinopathy, retinopathy of prematurity, branch retinal vein occlusion, central retinal vein occlusion, open-angle glaucoma, veovascular glaucoma, and other diseases of the retinal and/or optic nerve where an imbalance between metabolic demand and blood supply contribute to the development of tissue damage. The invention furthermore relates to pharmaceutical compositions comprising such compounds.
PCT/DK2005/000176 2004-03-17 2005-03-16 Prevention of retinopathy by inhibition of the visual cycle WO2005087210A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005221283A AU2005221283C1 (en) 2004-03-17 2005-03-16 Prevention of retinopathy by inhibition of the visual cycle
US10/593,261 US9421175B2 (en) 2004-03-17 2005-03-16 Prevention of retinopathy by inhibition of the visual cycle
NZ550340A NZ550340A (en) 2004-03-17 2005-03-16 Prevention of retinopathy by inhibition of the visual cycle using a retinoid
JP2007503197A JP2007529434A (en) 2004-03-17 2005-03-16 Prevention of retinopathy by inhibiting the visual cycle
CA2601278A CA2601278C (en) 2004-03-17 2005-03-16 Prevention of retinopathy by inhibition of the visual cycle
EP05715097.1A EP1727529B1 (en) 2004-03-17 2005-03-16 Prevention of retinopathy by inhibition of the visual cycle
IL178116A IL178116A (en) 2004-03-17 2006-09-14 Use of compounds comprising retinoids for preparation of a medicament and pharmaceutical compositions comprising the same for prevention and treatment of nonproliferative diabetic retinopathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400431 2004-03-17
DKPA200400431 2004-03-17

Publications (2)

Publication Number Publication Date
WO2005087210A2 WO2005087210A2 (en) 2005-09-22
WO2005087210A3 true WO2005087210A3 (en) 2005-11-10

Family

ID=34962025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000176 WO2005087210A2 (en) 2004-03-17 2005-03-16 Prevention of retinopathy by inhibition of the visual cycle

Country Status (10)

Country Link
US (1) US9421175B2 (en)
EP (1) EP1727529B1 (en)
JP (1) JP2007529434A (en)
KR (1) KR20070011379A (en)
CN (1) CN1964706A (en)
AU (1) AU2005221283C1 (en)
CA (1) CA2601278C (en)
IL (1) IL178116A (en)
NZ (1) NZ550340A (en)
WO (1) WO2005087210A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324823A3 (en) 2003-03-14 2011-11-16 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
HUE036596T2 (en) 2004-06-18 2018-07-30 Univ Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
EP2277516A1 (en) 2004-06-23 2011-01-26 ReVision Therapeutics, Inc. Retinyl derivatives for treating ophtalmic conditions
EP1807103A4 (en) 2004-11-04 2009-02-11 Sirion Therapeutics Inc Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
JP4178281B2 (en) * 2004-12-08 2008-11-12 シリオン セラピューティクス， インコーポレイテッド Methods, assays and compositions for treating retinol-related diseases
EP2069391A4 (en) * 2006-07-27 2009-12-30 Univ Florida Compositions and methods for treating or preventing ophthalmic disease
PT2187880E (en) 2007-09-12 2014-03-25 Univ Columbia Compositions and methods for treating macular degeneration
MY155320A (en) 2007-10-05 2015-09-30 Acucela Inc Alkoxy compounds for disease treatment
BRPI0908154A2 (en) 2008-02-11 2015-08-11 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunctions
WO2009105756A2 (en) * 2008-02-22 2009-08-27 Children's Medical Center Corporation Protection of neural retina by reduction of rod metabolism
ES2549916T3 (en) * 2009-05-04 2015-11-03 Acucela, Inc. Compositions for use in the treatment of glaucoma or ocular hypertension
IN2012DN00352A (en) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
EP4000610A1 (en) * 2009-07-02 2022-05-25 Acucela Inc. Pharmacology of visual cycle modulators
JP5663025B2 (en) 2009-09-15 2015-02-04 キューエルティー インコーポレイテッド Pharmaceutical formulation comprising 9-cis-retinyl ester in a lipid vehicle
RU2622763C2 (en) 2010-04-19 2017-06-19 Новелион Терапьютикс Инк. Regimen and methods of treatment or reduction of visual disturbances, associated with deficient endogenous retinoids
WO2013134867A1 (en) 2012-03-01 2013-09-19 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
TW201406707A (en) * 2012-05-04 2014-02-16 Acucela Inc Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522226A1 (en) * 1991-07-12 1993-01-13 Ciro Costagliola Eyedrop solution for the treatment of ocular hypertension containing ketauserin
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
WO2003004058A1 (en) * 2001-07-02 2003-01-16 Santen Pharmaceutical Co., Ltd. OPTIC NERVE PROTECTING AGENTS CONTAINING α1 RECEPTOR BLOCKER AS THE ACTIVE INGREDIENT
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
WO2005011741A2 (en) * 2003-07-10 2005-02-10 Allergan, Inc. Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle
WO2005056010A1 (en) * 2003-12-02 2005-06-23 Allergan, Inc. Prevention and/or reduction of photoreceptor degeneration with retinoids

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094783A (en) * 1990-06-29 1992-03-10 Uab Research Foundation Retinoid compounds
DE4234801A1 (en) 1992-10-15 1994-04-21 Bayer Ag Sulfonylaminocarbonyltriazolinone
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CN1050844C (en) 1993-12-07 2000-03-29 伊莱利利公司 Protein kinase C inhibitors
WO1997018809A1 (en) 1995-11-20 1997-05-29 Eli Lilly And Company Protein kinase c inhibitor
UA54427C2 (en) 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Method for treating eye diseases caused by vascular endotelium growth factor
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
WO1999058126A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
EP1296678A2 (en) 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
SE0100857D0 (en) 2001-03-13 2001-03-13 Tomas Hagstroem Treatment of tumors
CA2442917C (en) 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
DE60233655D1 (en) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R AND RETINOID X RECEPTOR MODULATORS
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1536819A4 (en) 2002-03-29 2007-10-17 Maxim Pharm Inc Use of rom production and release inhibitors to treat and prevent intraocular damage
WO2003097052A2 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
JP2006511445A (en) 2002-06-07 2006-04-06 コーティカル・ピーティーワイ・リミテッド Naphthalene derivatives that inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
WO2005058304A1 (en) 2003-12-17 2005-06-30 Cortical Pty Ltd Implantable device containing inhibitor of macrophage migration inhibitory factor
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522226A1 (en) * 1991-07-12 1993-01-13 Ciro Costagliola Eyedrop solution for the treatment of ocular hypertension containing ketauserin
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
WO2003004058A1 (en) * 2001-07-02 2003-01-16 Santen Pharmaceutical Co., Ltd. OPTIC NERVE PROTECTING AGENTS CONTAINING α1 RECEPTOR BLOCKER AS THE ACTIVE INGREDIENT
WO2005011741A2 (en) * 2003-07-10 2005-02-10 Allergan, Inc. Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle
WO2005056010A1 (en) * 2003-12-02 2005-06-23 Allergan, Inc. Prevention and/or reduction of photoreceptor degeneration with retinoids

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CALISSENDORFF B M: "RETINAL CHANGES DEGENERATION OR SIDE EFFECTS CAUSED BY ETRETINATE THERAPY TIGASON", KLINISCHE MONATSBLAETTER FUER AUGENHEILKUNDE, vol. 194, no. 3, 1989, pages 187 - 189, XP008049557, ISSN: 0023-2165 *
MARMOR M F ET AL: "Albipunctate retinopathy with cone dysfunction and no abnormality in the RDH5 or RLBP1 genes", RETINA 2003 UNITED STATES, vol. 23, no. 4, 2003, pages 543 - 546, XP008049556, ISSN: 0275-004X *
OIKAWA T ET AL: "THREE NOVEL SYNTHETIC RETINOIDS, RE 80, AM 580 AND AM 80, ALL EXHIBIT ANTI-ANGIOGENIC ACTIVITY IN VIVO", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 249, no. 1, November 1993 (1993-11-01), pages 113 - 116, XP000879175, ISSN: 0014-2999 *
WELEBER R G ET AL: "Abnormal retinal function associated with isotretinoin therapy for acne", ARCHIVES OF OPHTHALMOLOGY 1986 UNITED STATES, vol. 104, no. 6, 1986, pages 831 - 837, XP008049560 *
WROBEL A ET AL: "Antiangiogenic activity of agonist and antagonists of retinoid nuclear receptors", PRZEGLAD DERMATOLOGICZNY 1999 POLAND, vol. 86, no. 4, 1999, pages 339 - 346, XP000879096, ISSN: 0033-2526 *

Also Published As

Publication number Publication date
EP1727529B1 (en) 2016-03-02
CA2601278A1 (en) 2005-09-22
AU2005221283C1 (en) 2011-02-03
US20070249713A1 (en) 2007-10-25
US9421175B2 (en) 2016-08-23
CA2601278C (en) 2014-06-10
KR20070011379A (en) 2007-01-24
IL178116A (en) 2012-12-31
IL178116A0 (en) 2007-03-08
WO2005087210A2 (en) 2005-09-22
JP2007529434A (en) 2007-10-25
AU2005221283B2 (en) 2010-09-09
AU2005221283A1 (en) 2005-09-22
CN1964706A (en) 2007-05-16
EP1727529A2 (en) 2006-12-06
NZ550340A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
WO2005087210A3 (en) Prevention of retinopathy by inhibition of the visual cycle
WO2010056302A3 (en) Iontophoretic therapeutic agent delivery system
MX2010003774A (en) Aqueous ophthalmic formulations.
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2005089502A3 (en) Methods for the treatment of synucleinopathies
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2006047466A3 (en) Ophthamological drugs
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005099680A3 (en) Use of treprostinil to treat neuropathic diabetic foot ulcers
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
NO20073831L (en) Medications for the treatment or prevention of fibrotic diseases
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2005107705A3 (en) Extended therapeutic effect ocular implant treatments
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
WO2008006535A3 (en) Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases
WO2004028516A3 (en) Compositions for the inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
WO2005089504A3 (en) Methods for the treatment of synucleinopathies
WO2007105203A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
MY153112A (en) Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
SG170044A1 (en) Ocular allergy treatments
NO20076245L (en) Use of TFPI to treat severe bacterial infections
WO2007075923A3 (en) Treatment of synucleinopathies
WO2008013986A3 (en) Compositions and methods for treating or preventing ophthalmic light toxicity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007503197

Country of ref document: JP

Ref document number: 178116

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005715097

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 550340

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1212/MUMNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005221283

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067021548

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005221283

Country of ref document: AU

Date of ref document: 20050316

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005221283

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580015840.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005715097

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067021548

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10593261

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2601278

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 10593261

Country of ref document: US